China begins human coronavirus vaccine testing, a vaccine administered by nasal route - China has just approved clinical trials for a coronavirus vaccine administered via the nose, the University of Hong Kong has reported and local media have gathered.
Trials are expected to begin in November, but scientists warn that it will probably not be available for mass production until next year.
The Department of infectious diseases of the University of Hong Kong has developed the candidate together with Xiamen University and Wantai biologic Pharmacy in Beijing.
It is the first nasal administration vaccine to receive green light from China's National Administration of medical products to initiate human testing.
The university has received support and funding from the country's authorities since the project began and expects to recruit 100 young and healthy people in Hong Kong for trials.
China begins human coronavirus vaccine testing
The researchers have assured that, if proven effective, nasal administration can represent a huge advantage by tracking the natural entry of the virus into the body.
The candidate has been selected as one of the five coronavirus vaccine projects the Chinese government is betting on.
The announcement of this nasal vaccine comes hours after who anticipated that, despite initial optimism, the coronavirus vaccine will not be available to the majority of the population until 2022.
This Wednesday in fact AstraZeneca suspended trials of Phase III of its vaccine (which will arrive in Spain in December if all goes well) due to the adverse reaction of one of the patients. Hours later the EU confirmed the reserve of another 200 million doses, this time of the coronavirus vaccine from BioNTech and Pfizer.
End of China begins human coronavirus vaccine testing
A survey of 92 innovation managers shows what big companies look at before investing in a startup and what are the keys to making the relationship work
Large corporations have changed their innovation policy in recent times. They feel threatened by startups and seek to maintain their strong position in the market by investing in them. A phenomenon that continues to grow. It is increasingly common to see companies like Disney or Samsung investing part of their capital in young companies offering disruptive solutions.
At the beginning of the startup boom, large companies did not have a proper structure to encourage investment or qualified staff. So they chose to work with an external facilitator, in charge of identifying potential startups for the company. However, the boundaries in corporate enterprises are disappearing and it is now increasingly common for the corporate entrepreneurship team to take on this task.
"There are many methodologies that big companies have internalized," explains Diego Fernandez, CEO of Gellify, a platform that unites companies with startups.
This phenomenon has been investigated by Josemaria Siota, executive director of IESE corporate Venturing, in collaboration with Diego Fernandez and Telmo Perez, director of innovation at Acciona.
The Siota report " Open Innovation. Improve your capability, deal flow, cost and speed with a corporate venturing ecosystem", was presented during startup Olé, the international event of startups and technological entrepreneurship that is celebrating its sixth edition 100% online with the aim of adapting to the current situation caused by the coronavirus pandemic.
To find out how the innovation ecosystem works in large companies, 92 interviews were conducted with innovation managers from large companies around the world.
The result is that the most frequent aspects that companies evaluate when making the first decision to invest in are:
- Proximity of startups to the core business of the company (26% of cases),
- Internal capacity to work with entrepreneurs (24%)
- Opportunities to collaborate between both companies (17%)
- Implementation cost (11%).
- Time required to integrate it into the company's Business (7%)
- Knowledge of Technology (3%)
- Availability of necessary resources (3%)
- Other (9%)
One of the reasons for large companies to consider as a more determining factor that the startup is related to the sector in which they operate is to avoid the leakage of talent to their competitors. "There are certain fields that are very sensitive to the company, are strategic and require a high degree of confidentiality. This leads companies to invest to ensure close control and access first-hand information without intermediaries.", explains Siota.
During the presentation, innovation experts at Acciona and Gellifly have also revealed the keys that both the corporation and the startup must follow to build a successful relationship.
"I have often advised entrepreneurs to measure their efforts very well. The corporation is not always listening or listening to what the entrepreneur is proposing, " says Acciona's innovation director.
For Perez it is very important to identify a need or a person or team committed to promote the idea of the entrepreneur. "If you feel that person, team or need are not, stop pushing, because it can be a very badly invested time.", explain.
For this innovation expert, the relationship must have a component of effort on both sides. With the intention that each entrepreneur that is part of the portfolio of Acciona find the right person to solve their problems have enabled from the company a point of consultation.
For the CEO of Gellify the key to the relationship between the corporation and the entrepreneur is to define the focus, that is, to be very clear for what you want to start the relationship and what will be found both parties. "Before you sit down you have to be very clear that you will be able to process what you are opening," he explains.
For Fernandez, corporations should know that innovation is not just about buying a startup :" it means integrating a process for which you are sometimes not prepared. They have to understand that on the other side there are entrepreneurs and for them the matter is very important. You have to invest time in caring for them."